Article
26 Sep 2025
Amgen Fires Back With Counterclaims In Aflibercept BPCIA Litigation
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
19 May 2025
President Trump Issues Two Executive Orders Concerning The Affordability And Accessibility Of Drugs
Article
17 Jan 2025
Year In Review: Top Legal Developments Of 2024
Article
05 Sep 2024
Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilar
Article
20 Jun 2024
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation
Article
18 Jun 2024
Update On Aflibercept BPCIA Litigation
Article
16 Jan 2024
Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation And Regulation In The U.S.
Article
19 Oct 2023
Celltrion Expands Access To YUFLYMA (Adalimumab-Aaty)
Article
10 Mar 2023
Genentech Files Lawsuits Against Biogen And Millennium For Past Royalties On The Cabilly Patents
Article
22 Feb 2023
Genentech BPCIA Trastuzumab Case Against Tanvez Dismissed After Settlement
Article
31 Jan 2023
An Interview With Rachel Goode, Ph.D, About Biological Patent Thickets
Article
08 Nov 2022
Supreme Court Grants Cert To Address Enablement In Amgen Case
Article
02 Nov 2022
Biogen Seeks A Preliminary Injunction In Natalizumab BPCIA Case Against Sandoz
Article
02 Nov 2022
Regeneron Identifies Six Patents For Expedited Trial In BPCIA Aflibercept Case Against Mylan
Article
01 Nov 2022
Expedited Trial Ordered In Regeneron Aflibercept BPCIA Case Against Mylan
Article
03 Oct 2022
Celltrion's Bevacizumab Biosimilar Approved By FDA
Article
14 Sep 2022
Regeneron Seeks Expedited Trial In BPCIA Case Against Mylan Regarding Aflibercept Biosimilar
Article
13 Sep 2022
Biogen Files Sealed Complaint Against Sandoz And Polpharma Biologics Regarding Natalizumab
Article
08 Sep 2022
Tanvex Answers Genentech's Trastuzumab Complaint
Article
30 Aug 2022
Biosimilar Regulatory Approval Updates